137 related articles for article (PubMed ID: 17428156)
41. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
[TBL] [Abstract][Full Text] [Related]
42. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
43. Combining the hDAF transgene with the GP IIb/IIIa inhibitor tirofiban improves heart performance and reduces myocardial damage following hyperacute rejection in an ex vivo perfusion model.
Brandl U; Erhardt M; Joeckle H; Michel S; Brenner P; Bittmann I; Roessle M; Mordstein V; Hammer C; Schmoeckel M; Reichart B
Transplant Proc; 2005; 37(1):491-2. PubMed ID: 15808686
[TBL] [Abstract][Full Text] [Related]
44. Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis.
Schweizer J; Kirch W; Koch R; Müller A; Hellner G; Forkmann L
Angiology; 2003; 54(2):155-61. PubMed ID: 12678189
[TBL] [Abstract][Full Text] [Related]
45. The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anticoagulants used.
Aalto-Setälä K; Karhunen PJ; Mikkelsson J; Niemelä K
J Thromb Thrombolysis; 2005 Aug; 20(1):57-63. PubMed ID: 16133898
[TBL] [Abstract][Full Text] [Related]
46. High-dose, bolus-only, glycoprotein IIb/IIIa inhibitors for elective coronary intervention: logical, safe, cost-effective, and it works!
Fischell TA
J Invasive Cardiol; 2008 Feb; 20(2):59-60. PubMed ID: 18252968
[No Abstract] [Full Text] [Related]
47. Treatment of acute central retinal artery occlusionwith the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban.
Hölschermann H; Krombach C; Jung A; Jacobi F; Tillmanns H; Weinand F
Thromb Haemost; 2005 Sep; 94(3):684-6. PubMed ID: 16268493
[No Abstract] [Full Text] [Related]
48. Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade.
Durand M; Lecompte T; Hacquard M; Carteaux JP
Eur J Cardiothorac Surg; 2008 Sep; 34(3):687-9. PubMed ID: 18579401
[TBL] [Abstract][Full Text] [Related]
49. Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis.
Rukshin V; Azarbal B; Finkelstein A; Shah PK; Cercek B; Tsang V; Kaul S
J Cardiovasc Pharmacol; 2003 Apr; 41(4):615-24. PubMed ID: 12658064
[TBL] [Abstract][Full Text] [Related]
50. Practical issues of platelet glycoprotein IIb/IIIa receptor inhibition: saving lives and saving money.
Dippel EJ
Rev Cardiovasc Med; 2002; 3 Suppl 1():S28-34. PubMed ID: 12439434
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.
Zhou X; Wu X; Sun H; Li J
J Evid Based Med; 2017 May; 10(2):136-144. PubMed ID: 28449419
[TBL] [Abstract][Full Text] [Related]
52. Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration.
Tucci MA; Ganter MT; Hamiel CR; Klaghofer R; Zollinger A; Hofer CK
J Thorac Cardiovasc Surg; 2006 Jun; 131(6):1314-22. PubMed ID: 16733164
[TBL] [Abstract][Full Text] [Related]
53. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events.
Dunkley S; Evans S; Gaudry L; Jepson N
Platelets; 2005 Dec; 16(8):462-8. PubMed ID: 16287613
[TBL] [Abstract][Full Text] [Related]
54. Use of GPIIb/IIIa inhibitors in cardiovascular medicine.
Ahrens I; Peter K; Bode C
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):233-42. PubMed ID: 15030283
[TBL] [Abstract][Full Text] [Related]
55. Effectiveness of tirofiban for failed thrombolysis during acute myocardial infarction.
Vetrano A; Carotenuto R; Corsini F; Schioppa M; Martone A; Melorio S; Sideri F; Romano S; Chieffo C; Corsini G
Am J Cardiol; 2004 Apr; 93(7):914-6. PubMed ID: 15050497
[TBL] [Abstract][Full Text] [Related]
56. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment.
Mulot A; Moulin F; Fohlen-Walter A; Angioi M; Sghaier M; Carteaux JP; Lecompte T; de Maistre E
Am J Hematol; 2004 Sep; 77(1):67-71. PubMed ID: 15307109
[TBL] [Abstract][Full Text] [Related]
57. The role of tirofiban in the management of coronary artery disease.
Winter JP; Juergens CP
Cardiovasc Hematol Disord Drug Targets; 2008 Jun; 8(2):138-46. PubMed ID: 18537601
[TBL] [Abstract][Full Text] [Related]
58. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention.
Danzi GB; Capuano C; Sesana M; Baglini R
Curr Med Res Opin; 2003; 19(1):28-33. PubMed ID: 12661777
[TBL] [Abstract][Full Text] [Related]
59. Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor.
Gül C; Kürüm T; Demir M; Ozbay G; Vural O; Iqbal O; Fareed J
Clin Appl Thromb Hemost; 2004 Jan; 10(1):77-9. PubMed ID: 14979411
[TBL] [Abstract][Full Text] [Related]
60. GP IIb/IIIa antagonists. Clinical experience and potential uses in cardiology.
Kleiman NS
Drugs R D; 1999 May; 1(5):361-70. PubMed ID: 10566065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
